• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Phase II trial to study DME

Article

The Juvenile Diabetes Research Foundation (JDRF) is enrolling patients in a study to test the long-term safety and effectiveness of intraocular injections of ranibizumab (Lucentis, Genentech) in patients with diabetic macular edema (DME)

New York-The Juvenile Diabetes Research Foundation (JDRF) is enrolling patients in a study to test the long-term safety and effectiveness of intraocular injections of ranibizumab (Lucentis, Genentech) in patients with diabetic macular edema (DME)

The Ranibizumab for Edema of the Macula in Diabetes phase II (READ 2) study, supported by Genentech and JDRF, builds on the results of the foundation's phase I trial. In that trial, ranibizumab was shown to improve visual acuity in patients with DME, with no adverse events related to the drug. Median and mean visual acuity improved by 11 and 12.3 letters respectively at 7 months.

READ 2 will look at additional dosing and safety information, as well as combination therapy of ranibizumab and laser photocoagulation.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.